VanEck ETF Trust. Holdings as of Jun 30, 2026, from Form N-PORT.
Share of net assets at the report date, for the whole fund across all share classes.
| Holding | Weight | Value | Shares or units |
|---|---|---|---|
| Amgen IncAMGN | 15.25% | $60.32M | 166,568 |
| Gilead Sciences IncGILD | 12.79% | $50.58M | 400,338 |
| Vertex Pharmaceuticals IncVRTX | 9.10% | $36.01M | 72,485 |
| Regeneron Pharmaceuticals IncREGN | 6.21% | $24.56M | 39,388 |
| Revolution Medicines IncRVMD | 5.27% | $20.86M | 111,381 |
| Argenx SEARGX | 4.97% | $19.67M | 21,198 |
| Natera IncNTRA | 4.92% | $19.46M | 71,677 |
| IQVIA Holdings IncIQV | 4.31% | $17.03M | 88,160 |
| Alnylam Pharmaceuticals IncALNY | 3.83% | $15.16M | 50,358 |
| Biogen IncBIIB | 3.63% | $14.35M | 66,394 |
| Moderna IncMRNA | 3.36% | $13.30M | 189,951 |
| Illumina IncILMN | 3.17% | $12.54M | 71,334 |
| United Therapeutics CorpUTHR | 2.83% | $11.18M | 20,628 |
| BeOne Medicines LtdONC | 2.81% | $11.11M | 38,996 |
| Insmed IncINSM | 2.67% | $10.56M | 99,048 |
| Incyte CorpINCY | 2.49% | $9.86M | 86,946 |
| Neurocrine Biosciences IncNBIX | 2.08% | $8.24M | 48,865 |
| BioNTech SEBNTX | 1.94% | $7.68M | 82,542 |
| ICON PLC | 1.90% | $7.52M | 43,319 |
| Bio-Techne CorpTECH | 1.54% | $6.10M | 86,310 |
| Charles River Laboratories International IncCRL | 1.50% | $5.94M | 26,203 |
| BioMarin Pharmaceutical IncBMRN | 1.34% | $5.29M | 92,530 |
| QIAGEN NV | 1.06% | $4.21M | 107,713 |
| Tempus AI IncTEM | 0.98% | $3.89M | 67,091 |
| State Street Global AdvisorsCash or money market | 0.06% | $233.72K | 233,716 |
Holdings from the fund's latest Form N-PORT; expense ratio (net of fee waivers) from the risk/return summary of its prospectus; fund type from Form N-CEN. Prices are end-of-day closes adjusted for splits; total return also reinvests distributions.